686772-17-8

基本信息
2-((3-(2-甲氧基苯基)-4-氧代-3,4,6,7-四氢噻吩并[3,2-D]嘧啶-2-基)硫代)-N-(6-甲基苯并[D]噻唑-2-基)乙酰胺
CS-2394
IWP4
IWP 4
IWP-4 >=95% (HPLC)
Wnt Inhibitor IWP-4
Inhibitor of Wnt Production-4
N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-3-(2-methoxyphenyl)-4-oxothieno[3,2-d]pyrimidin-2-yl)thio]-acetamide
Acetamide, N-(6-methyl-2-benzothiazolyl)-2-[[3,4,6,7-tetrahydro-3-(2-methoxyphenyl)-4-oxothieno[3,2-d]pyrimidin-2-yl]thio]-
2-((3-(2-methoxyphenyl)-4-oxo-3,4,6,7-tetrahydrothieno[3,2-d]pyrimidin-2-yl)thio)-N-(6-methylbenzo[d]thiazol-2-yl)acetamide
物理化学性质
密度 | 1.51±0.1 g/cm3(Predicted) |
储存条件 | -20°C |
溶解度 | insoluble in H2O; insoluble in EtOH; insoluble in DMSO |
酸度系数(pKa) | 9.01±0.70(Predicted) |
形态 | 粉末 |
颜色 | 白色至浅棕色 |
安全数据
危险性符号(GHS) | ![]() GHS07 |
警示词 | 警告 |
危险性描述 | H302 |
防范说明 | P280-P305+P351+P338 |
WGK Germany | 3 |
CS-2394价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/02/08 | HY-12879 | IWP-4 | 686772-17-8 | 1 mg | 438元 |
2025/02/08 | HY-12879 | CS-2394 IWP-4 | 686772-17-8 | 5mg | 1500元 |
2025/02/08 | HY-12879 | CS-2394 IWP-4 | 686772-17-8 | 10mg | 2500元 |
常见问题列表
IC50: 25 nM (Wnt)
IWP-4 is a small molecule Wnt inhibitor with an IC 50 of 25 nM. IWP-4 induces the expression of cardiac markers, including cardiac troponin I (CTNI) and cardiac myosin heavy chain bright cells (MYH hi + ). IWP-4 also results in the appearance of beating foci (0.44±0.10 SEM beats per second), which is absent in all cultures not receiving IWP-4. Further, flow cytometric analysis shows that there are significantly more MYH lo + cells in IWP-4 treated cultures (P<0.0002) compare with untreated cultures at day 16, being 17.0±1.3 SD% and 5.4±1.4 SD%, respectively. Quantification of NKX2-5 protein expression shows that 63% (481/817) of IWP-4 treated cells display nuclear NKX2-5 expression. Mesenchymal precursor cells (MPCs) treated with IWP-4 show no significant changes in the expression of AXIN2 , CTNNB1 and GSK3B as compare to osteogenic medium alone on day 7, but MPCs treated with IWP-4 express elevates levels of DKK1 and GSK3β on day 21. IWP-4 also causes a significant down regulation of SPARC and COL1A1 .